{"denomUnitsSelected":"Participants","description":"Will evaluate baseline tumor and blood-based markers as predictors of benefit from the addition of palbociclib to anti-HER2 therapy plus endocrine therapy","reportingStatus":"NOT_POSTED","timeFrame":"Baseline","title":"Tumor Tissue Biomarkers Including Genes, Proteins, and RNA Expression","type":"OTHER_PRE_SPECIFIED"}